Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Does This News Make Inovio Pharmaceuticals Stock a Buy?

TheMotleyFool

0 0

Does This News Make Inovio Pharmaceuticals Stock a Buy?

It's been a rough 12 months for Inovio Pharmaceuticals (NASDAQ: INO). In the past year, shares of the company have declined by 35% while the S&P 500 has risen 30%. The main reason for this abysmal showing was Inovio's inability to keep up with some of its peers, such as Moderna, in the race to develop a coronavirus vaccine.

However, the biotech recently announced some encouraging regulatory news on that front. Let's look into the latest developments regarding Inovio's attempt to market its investigational coronavirus vaccine, INO-4800, and whether it is worth purchasing shares of the vaccine maker today.